Expert Interview
Discussing the Potential of United Therapeutics' Tyvaso to Treat Earlier Line IPF Based on Results from TETON-1/ TETON-2 Trial Data
Ticker(s): UTHR, RHHBY, INSM, Boehringer IngelheimInstitution: Loma Linda University Health
- Assistant Professor of Medicine and Director, Interstitial Lung Disease Program at Loma Linda University Health
- Manages 100 patients with IPF
- Clinical interests in Pulmonary Vascular Conditions and Obstructive Lung Disease including IPF, Hypersensitivity Pneumonitis, Langerhans Cell Histiocytosis; Research focus on Pulmonary rehabilitation of patients with IPF
How many IPF patients do you manage?
Added By: wilson_adminHow do you currently managing IPF?
Added By: wilson_adminWhat is your opinion on how data from the TETON 1 and 2 trials may change your treatment algorithm?
Added By: wilson_adminWhat is your excitement for tyvaso on a scale of 1-10 for IPF?
Added By: ben_adminAre You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
